ICON’s novel RNA-based NGS assay, Dup-Seq BCR::ABL1, represents a significant advancement in the management of CML patients.

Based on RNA technology, ICON’s new assay offers huge improvements on how CML is monitored ... NGS assay known as Dup-Seq BCR::ABL1. This innovative assay enables the identification of both ...